Patient-Reported Discontinuation of Endocrine Therapy and Related Adverse Effects Among Women With Early-Stage Breast Cancer
- 1 November 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (6), e149-e157
- https://doi.org/10.1200/jop.2012.000543
Abstract
Few individual adverse effects or patient characteristics were significantly associated with endocrine therapy discontinuation, yet adverse effects were prevalent and were the most commonly reported reason for discontinuation.This publication has 35 references indexed in Scilit:
- Endocrine Therapy Initiation From 2001 to 2008 Varies by Age at Breast Cancer Diagnosis and Tumor SizeJournal of Oncology Practice, 2012
- Challenges to physician–patient communication about medication use: a window into the skeptical patient’s worldPatient Preference and Adherence, 2011
- Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancerBreast Cancer Research and Treatment, 2011
- Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancerBritish Journal of Cancer, 2011
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008
- Patient Centered Experiences in Breast CancerMedical Care, 2007
- Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.Journal of the National Comprehensive Cancer Network, 2006
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older WomenJournal of Clinical Oncology, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987